In 2023, mental health disorders affected over 59 million people in the United States. Over 19.1% of American adults had anxiety disorders, 8.5% had a major depressive episode, 2.8% had bipolar disorder, and less than 1% had schizophrenia. With the increase in attention to mental health, especially since the start of the COVID-19 pandemic, and the development of new therapies like esketamine, pharmacists and pharmacy technicians should continuously review any updates regarding psychiatric medication use and safety. This CE article will review common mental health disorders (major depression, anxiety disorders, bipolar disorder, schizophrenia), pharmacologic treatment options, and important updates regarding the medication management of these patient populations.

Acknowledgement of Support

This article is supported by an unrestricted educational grant from the Cardinal Health Foundation.